Wednesday, May 1, 2019

A promising new treatment for infants with Noonan syndrome

Infants less than six months old with Noonan Syndrome, hypertrophic cardiomyopathy and congestive heart failure normally have a poor prognosis, with a one-year survival rate of 34 percent. In the new study, doctors used Trametinib to try to treat NS in two patients. They observed dramatic improvement of clinical and cardiac status in the patients only three months after treatment.

from Top Health News -- ScienceDaily http://bit.ly/2LefK3m

No comments:

Post a Comment

Stem cell pain sponge soaks up osteoarthritis joint pain and protects cartilage

SereNeuro Therapeutics revealed promising results for SN101, a first-in-class iPSC-derived therapy designed to treat chronic osteoarthritis ...